Telehealth In The Media

Primary outcome measures:
Pathologic complete response (pCR) rate assessed by independent central pathology review [Time Frame: Up to 12 weeks]

Secondary outcome measures:

1. Major pathologic response (mPR) rate assessed by independent central pathology review [Time Frame: Up to 12 weeks]
2. pCR rate assessed by local pathology review [Time Frame: Up to 12 weeks]
3. mPR rate assessed by local pathology review [Time Frame: Up to 12 weeks]
4. Objective response rate (ORR) prior to surgery, according to investigator assessment using RECIST 1.1 [Time Frame: Up to 12 weeks]
5. Event free survival (EFS) [Time Frame: Up to 50 months]
6. Disease free survival (DFS) [Time Frame: Up to 47 months]
7. Overall survival (OS) [Time Frame: Up to 50 months]
8. Incidence of adverse events (AEs) [Time Frame: Up to 52 months]
9. Incidence of serious adverse events (SAEs) [Time Frame: Up to 52 months]
10. Incidence of deaths [Time Frame: Up to 52 months]
11. Incidence of laboratory abnormalities [Time Frame: Up to 52 months]
12. Change in surgical plan in the screening period versus actual surgery after neoadjuvant cemiplimab [Time Frame: Up to 12 weeks]
13. Change in post-surgical management plan in the screening period versus actual post-surgical management [Time Frame: Up to 14 weeks]

Key Inclusion Criteria:

1. Stage II to IV (M0) CSCC, for which surgery would be recommended in routine clinical practice. For stage II patients, lesion must be ≥3 cm at the longest diameter.
2. At least 1 lesion that is measurable by RECIST 1.1
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
4. Adequate organ, bone marrow function, and hepatic function as defined in the protocol

Key Exclusion Criteria:

1. Solid malignancy within 5 years of the projected enrollment date, or hematologic malignancy (including chronic lymphocytic leukemia [CLL]) at any time
2. Distant metastatic disease (M1), visceral and/or distant nodal
3. Prior radiation therapy for CSCC
4. Patients with a condition requiring corticosteroid therapy (>10 mg prednisone/day or equivalent) within 14 days of the first dose of study drug.
5. Patients with active, known, or suspected autoimmune disease that has required systemic therapy within 5 years of the projected enrollment date.
6. History of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management.
7. Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C virus (HBV or HCV) infection; or diagnosis of immunodeficiency
8. Active tuberculosis

NOTE: Other protocol-defined Inclusion/Exclusion Criteria apply

Main inclusion criteria:

1. Must be a new or established patient seen in the dermatology clinic, > 12 years old, and your provider must recommend NB-UVB (narrow band ultra violet) phototherapy (also called light therapy) for the treatment of psoriasis.

Main inclusion criteria:

1. Clinical diagnosis of PN for at least 6 months.
    
2. Have at least 20 nodules of approximately 0.5 to 2 cm. The nodules must be pruritic and present on at least 2 different anatomical locations (not be localized), involve the extremities, with extensor extremity involvement greater than the flexor extremity involvement. Nodules on the head (face and scalp) are not counted as an anatomical location for eligibility criteria. Each arm, each leg, and trunk are considered different anatomical locations. IGA score of ≥3.
    
3. Subject has moderate to severe pruritus, defined as WI-NRS ≥7.

Main inclusion criteria:

1. Clinical diagnosis of PN for at least 6 months with Pruriginous nodular lesions on upper limbs, trunk, and/or lower limbs. At least 20 nodules on the entire body with a bilateral distribution with IGA score ≥ 3.
    
2. Severe pruritus defined as ≥ 7 on the PP NRS.
    
3. Lack of any other primary pruritic skin condition.

Main inclusion criteria:

1. Individuals diagnosed with generalized PN, defined as the presence of ≥ 10 pruriginous nodules, involving at least 2 distinct anatomical areas: for example, either 2 limbs; or a single limb and some axial portion of the body.
    
2. If there is any history of a primary pruritic skin condition other than PN, that condition must have been inactive for at least 6 months prior to screening.

Main inclusion criteria:

1. Atopic Dermatitis with IGA ≥ 3 or use of biologics.

Main inclusion criteria:

1. Chronic AD for at least 2 years with EASI ≥ 16 and IGA score ≥ 3. AD involvement ≥ 10% of body surface area.
    
2. Documented recent history (within 6 months) of inadequate response to TCS.
    
3. Documented recent history (within 6 months) of inadequate response to TCI if the patient has been using TCI.